Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Resistant Bipolar Depression Clear all

Conditions: Bipolar Depression
Interventions: Medtronic Percept RC System, One Month Blinded Discontinuation Period; Device · Behavioral
Lead sponsor: Wayne Goodman MD; Other
Eligibility: 22 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Houston, Texas • Seattle, Washington

Conditions: Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions: Ketamine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bipolar Disorder
Interventions: Ketamine hydrochloride injection, Flat tonic water (e.g., Canada Dry Tonic Water); Drug
Lead sponsor: Juvenile Bipolar Research Foundation; Other
Eligibility: 6 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Not Predetermined, Connecticut • Maplewood, New Jersey • Not Predetermined, New Jersey + 1 more

Conditions: Bipolar Disorder, Insulin Resistance
Interventions: Pioglitazone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder
Interventions: Deep Brain Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Treatment Resistant Depression
Interventions: Psilocybin; Drug
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions: LCHF Ketogenic Diet, Diet-as-Usual (DAU); Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Treatment Resistant Depression, Major Depressive Episode, Major Depression, Major Depressive Disorder, Bipolar Disorder, Bipolar Depression, Obsessive-Compulsive Disorder
Interventions: Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Ketamine, Esketamine, Deep Transcranial Magnetic Stimulation (dTMS); Device · Drug
Lead sponsor: Mark Niciu; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2050
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Bipolar Disorder I, Bipolar II Disorder, Bipolar I Disorder, Bipolar Disorder, Bipolar Depression, Bipolar and Related Disorders, Bipolar Disorder, Type 1, Bipolar Disorder, Type 2, Bipolar Disorder, Mixed, Obesity, Metabolic Syndrome, Ketogenic Dieting, Weight Gain, Brain Metabolic Disorder, Psychotropic Agents Causing Adverse Effects in Therapeutic Use
Interventions: LCHF Ketogenic Diet; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents, Analgesics, Peripheral Nervous System Agents, Physiological Effects of Drugs, Anesthetics, Dissociative, Anesthetics, General, Anesthetics, Central Nervous System Depressants, Excitatory Amino Acid Antagonists, Excitatory Amino Acid Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Ketamine, Depression, Unipolar, Depressive Symptoms, Treatment Resistant Depression, Major Depressive Disorder, Depression, Bipolar
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar II Disorder, Bipolar II Disorder, Most Recent Episode Major Depressive
Interventions: Device: Stimulation-ON, Device: Stimulation-OFF, Device: Stimulation -ON Active Control; Device
Lead sponsor: Andrew Krystal; Other
Eligibility: 22 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bipolar Disorder
Interventions: Felbamate; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bipolar Depression, Treatment Resistant Bipolar Depression
Interventions: Ketamine, Functional magnetic resonance imaging (fMRI); Drug · Other
Lead sponsor: Drew Cumming; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio • Ohio City, Ohio

Conditions: Depression
Interventions: VNS Therapy; Device
Lead sponsor: Cyberonics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 26
States / cities: Tucson, Arizona • Sacramento, California • Marietta, Georgia + 21 more

Conditions: Treatment Resistant Depression
Interventions: Lithium, Placebo, Ketamine; Drug
Lead sponsor: William V. Bobo, M.D.; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Bipolar II Disorder, Most Recent Episode Major Depressive, Current Depressive Episode, Treatment Resistant Depression
Interventions: Active Comparator: Active aiTBS, Sham Comparator: Sham aiTBS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Treatment Resistant Depression, Depressive Disorder, Treatment-Resistant, Depression, Bipolar
Interventions: SCC DBS; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Metabolic Syndrome, Bipolar Depression, Insulin Resistance
Interventions: Pioglitazone; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Treatment-resistant Bipolar Depression
Interventions: Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs), Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar Disorder
Interventions: MagStim; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Bipolar Disorder, Depression, Bipolar Depression
Interventions: SAMe, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Bipolar Disorder
Interventions: magnetic seizure therapy (MST), electroconvulsive therapy (ECT); Device
Lead sponsor: Joao L. DeQuevedo; Other
Eligibility: 22 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bipolar Depression, Treatment Resistant Depression
Interventions: Intensive intermittent theta-burst stimulation (iTBS); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
Interventions: MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner, ECT device without stimulation; Device · Other
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 25 Years to 64 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Deep Brain Stimulation of Treatment-Resistant Bipolar Depression

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder

Pioglitazone for the Treatment of Bipolar Depression

Deep Brain Stimulation for Treatment Resistant Depression

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

University of Iowa Interventional Psychiatry Service Patient Registry

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness

Natural History of Depression, Bipolar Disorder and Suicide Risk

Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression

Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression

FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

Study Comparing Outcomes for Patients With Treatment Resistant Depression Who Receive VNS Therapy at Different Doses

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Accelerated Intermittent Theta-Burst Stimulation (aiTBS) in Treatment-Resistant Depression of Bipolar II Disorder

Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression

Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Bipolar Depression

A Trial of SAMe for Treatment-Resistant Bipolar Depression

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

Intensive TMS for Bipolar Depression

Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)